Hippo ERcast August 2024

Then and Now

Emergency medicine practice has shifted toward faster, more patient-centered decisions in common ED problems. Shoulder dislocation management is moving away from routine pre-reduction X-rays in selected patients, acute asthma care now favors discharge inhaled corticosteroids, and chest pain evaluation leans on high-sensitivity troponin plus EKG over older scores and CK-MB. Evolving Emergency Medicine Practice Shoulder dislocation workflow: Anterior shoulder dislocation can often be reduced first and imaged afterward when the presentation is straightforward, cutting delay and discomfort for patients. We get into the practical bedside judgment in the episode. Post-reduction imaging priority: A post-reduction X-ray remains the key confirmation step, documenting successful relocation and screening for associated fracture or other reduction-related surprises. Asthma discharge controller therapy: Acute asthma exacerbations should not end with bronchodilators alone; adding an inhaled corticosteroid at discharge aligns with newer guidance and may reduce return visits and systemic steroid exposure. Younger patient steroid harms: Systemic corticosteroids carry real downside, especially in younger patients who are more likely to feel cumulative adverse effects, making inhaled controller therapy a meaningful practice shift. Chest pain risk stratification: Chest pain disposition is relying less on TIMI and CK-MB and more on serial high-sensitivity troponin plus EKG, a change that safely supports more ED discharges in selected patients. Evidence over habit: The through-line is abandoning legacy routines when newer evidence offers equal or better safety with less friction, a pattern we walk through on the show.

Understanding Oral Hyperglycemic Agents

Type 2 diabetes medications now span multiple oral classes with very different hypoglycemia risk, renal considerations, and ED implications. Sulfonylureas and meglitinides are the oral agents most likely to explain recurrent hypoglycemia, while metformin remains the usual first discharge choice for newly diagnosed type 2 diabetes when follow-up is uncertain. ED Approach to Oral Diabetes Drugs Medication list review: Unfamiliar diabetes drugs are now common in the ED, and the fastest high-yield step is a deliberate medication reconciliation focused on agents that raise insulin versus those that do not. We lay out the practical categories in the episode. Hyperglycemia syndromes: HHS points to severe hyperglycemia with neurologic symptoms but no acidosis, while DKA adds an anion gap metabolic acidosis and ketonemia despite a similar glucose range. Discharge glucose targets: There is no evidence-based ED glucose number that guarantees safe discharge; the useful point is clinical stability, not a magic cutoff, and the threshold debate is worth hearing in the chapter. Common adverse effects: GI upset is the class-wide side effect you will hear about most often, so taking these medications with food is practical advice, while renal injury is less common but matters for follow-up labs. Metformin first choice: Metformin decreases hepatic gluconeogenesis, does not increase insulin levels, and alone does not cause hypoglycemia, making it the go-to oral start for many newly diagnosed patients headed home. High-Risk and Lower-Risk Medication Classes Sulfonylurea hypoglycemia risk: Sulfonylureas are insulin secretagogues with long half-lives, so glyburide, glipizide, and glimepiride can produce recurrent hypoglycemia that outlasts an initial ED correction. Meglitinide comparison: Repaglinide and nateglinide are shorter-acting secretagogues dosed with meals, so they carry less prolonged hypoglycemia risk than sulfonylureas even though the mechanism is similar. Metformin renal caution: Metformin is generally hypoglycemia-sparing, but acute severe kidney injury raises concern for accumulation and the rare complication of lactic acidosis. SGLT2 urinalysis clue: SGLT2 inhibitors block renal glucose reabsorption, so marked glucosuria on urinalysis can be a medication effect rather than a diagnostic surprise; we get into the bedside implications in the podcast. Low hypoglycemia classes: GLP-1 agonists, DPP-4 inhibitors, thiazolidinediones, and alpha-glucosidase inhibitors have low standalone hypoglycemia risk because they do not drive sustained unregulated insulin release.

Lit Matters #1: Debunking STEMI Dogma

Right ventricular STEMI is not the nitroglycerin contraindication many of us were taught. In suspected RVMI, nitrate-associated hypotension appears uncommon, transient, and fluid responsive, and current evidence does not show worse adverse events than STEMI in other territories. Nitroglycerin in Right Ventricular STEMI Dogma versus evidence: The classic 'never give nitro in RVMI' rule rests on surprisingly thin historical data, while newer pooled evidence challenges the strength of that contraindication. Preload dependence framing: Right ventricular infarction is still a preload-sensitive state, but the feared nitrate effect is usually brief hypotension rather than catastrophic collapse. Meta-analysis signal: Across 1,113 patients, pooled data found no meaningful increase in adverse events or death when nitrates were used in RVMI compared with MI elsewhere. Typical adverse effect: Hypotension was the main complication, and in the included studies it was generally mild, transient, and responsive to fluids rather than a reason to avoid nitrates outright. Practical bedside takeaway: For suspected RVMI within an inferior STEMI, low- to moderate-dose nitroglycerin looks far less dangerous than dogma suggests, and we get into the bedside nuance in the episode. Important study limitation: Most included studies grouped right ventricular and inferior MI together, so the evidence is reassuring but not a blank check for every isolated RV infarct scenario.

Cystic Fibrosis: Much More Than a Pulmonary Disease

Cystic fibrosis is a systemic secretory disease, not just a lung problem, and adults with CF now present to the ED with both pulmonary exacerbations and end-organ complications. Pulmonary decline still drives most visits, but pneumothorax, hemoptysis, cor pulmonale, pancreatic insufficiency, and biliary disease all change emergency management. Cystic Fibrosis in the ED Systemic secretory disease: CFTR dysfunction dehydrates secretions across the lungs, pancreas, intestines, biliary tree, and sweat glands, making cystic fibrosis a multi-organ disease rather than an isolated pulmonary diagnosis. Pulmonary exacerbation pattern: Pulmonary exacerbations drive most ED presentations and typically show increasing dyspnea, tachypnea, hypoxia, sputum change, and worsening adventitious sounds on top of chronic productive cough. Patient-guided management: Many patients with CF know their baseline regimen, prior culture history, and which airway-clearance therapies help them most; that shared decision-making matters in the ED, and we get into the bedside approach in the episode. Imaging first principles: Chest radiography is the default first study in a suspected exacerbation, with hyperinflation often appearing early; compare with prior films to separate chronic bronchiectatic change from new pathology. COPD-like initial care: Initial treatment parallels COPD exacerbation care with oxygen support, bronchodilators, and secretion management, but airway clearance is central and anticholinergics may outperform beta-agonists in some patients. Culture-directed antibiotics: Pseudomonas aeruginosa is the signature pathogen and chronic colonization is common, so sputum cultures and prior microbiology should guide therapy rather than assuming a new organism each time. Complications Beyond Pulmonary Exacerbation Pneumothorax risk rises: Pneumothorax becomes more common with age in CF, often from ruptured subpleural blebs, and pleural interventions can complicate future lung transplant planning. Hemoptysis warning sign: Hemoptysis reflects bronchiectatic airway injury and inflammatory angiogenesis; most cases are self-limited, but severe bleeding may require bronchial artery embolization or surgery. ABPA and wheezing: Marked wheezing in CF is not always a routine exacerbation; allergic bronchopulmonary aspergillosis is a key alternate diagnosis even though Aspergillus isolation alone is common. Right heart failure clues: Advanced pulmonary disease can progress to pulmonary hypertension and cor pulmonale, with tender hepatomegaly and ascites serving as useful bedside clues during a hypoxic decompensation. Pancreatic and biliary disease: Pancreatic insufficiency starts early, and liver disease is a major cause of death in CF, so elevated transaminases, gallstones, portal hypertension, and variceal bleeding all belong on the ED differential.

High Risk, Low Prevalence: Guillain-Barré syndrome

Guillain-Barré syndrome is an immune-mediated peripheral neuropathy that classically causes symmetric ascending weakness with hyporeflexia or areflexia. Early bedside recognition matters because respiratory failure and dysautonomia can evolve over days to weeks, even when the first complaint is just distal paresthesias or burning pain. Bedside recognition of Guillain-Barré Classic weakness pattern: GBS usually presents with symmetric ascending weakness beginning in the feet, often after mild distal paresthesias or burning pain rather than major sensory loss. Reflex change clue: Hyporeflexia or areflexia is a high-yield bedside finding, with deep tendon reflex changes present in about 90% of patients. Recent trigger history: About 75% of patients have an antecedent trigger such as GI illness, URI, vaccination, surgery, pregnancy, or even myocardial infarction, a timeline we get into in the episode. Cranial nerve involvement: More than half of patients develop ocular, facial, or bulbar weakness, a pattern that should raise concern for impending airway compromise. Miller-Fisher variant: Ophthalmoplegia, ataxia, and areflexia point to Miller-Fisher syndrome, a GBS variant that may have relatively little limb weakness. Diagnosis and emergency management Clinical diagnosis first: GBS remains a clinical diagnosis supported by testing, while labs and imaging help exclude mimics such as hypokalemia, hypophosphatemia, and spinal cord disease. CSF protein pattern: Albuminocytologic dissociation with elevated CSF protein and a normal cell count supports GBS, but it is often absent in the first few days. We cover when that early negative LP should not reassure you in the chapter. Progression and symmetry: Weakness that worsens over days to weeks, stays symmetric, and lacks severe sensory deficits fits GBS better than stroke, myelopathy, or chronic neuropathy. Autonomic instability risk: About two-thirds of patients develop dysautonomia with blood pressure swings or tachyarrhythmias, and only persistent abnormalities generally merit treatment. Airway warning signs: Bulbar weakness, poor secretion handling, weak cough, and an abnormal single-breath count are practical red flags for respiratory decompensation. Definitive treatment options: IVIG and plasma exchange are the main disease-directed therapies and appear similarly effective, while combining them does not improve outcomes.

Lit Matters #2: A new approach to central venous line placement

Ultrasound-guided internal jugular access remains the default central venous catheter approach in emergency medicine, but the supraclavicular subclavian route may offer better first-pass success. Immediate complication rates including arterial puncture and pneumothorax were similar across neck and periclavicular sites in this review. Ultrasound CVC Site Selection Internal jugular default choice: IJ access remains a solid emergency department standard because it is familiar, ultrasound-friendly, and not clearly inferior to other sites on immediate safety outcomes. Supraclavicular subclavian edge: The supra-subclavian approach had the best first-pass performance in the network meta-analysis, with a relative improvement of about 22% over comparators. Arterial puncture comparison: Arterial puncture rates did not differ meaningfully from IJ across supra-subclavian, infra-subclavian, or axillary approaches, which is the key safety reassurance here. Pneumothorax signal: Pneumothorax was not meaningfully higher than IJ for the alternative approaches studied, despite the usual concern around subclavian-region cannulation. Hematoma reduction possibility: Supra-subclavian access may reduce hematoma compared with IJ, an interesting possible advantage that we put in practical context in the episode. Distal axillary drawback: Distal axillary access had the weakest first-pass success, making it a less attractive option when procedural efficiency matters. How To Apply The Evidence Expert operator limitation: All lines in the included trials were placed by expert operators, so the apparent benefit of supra-subclavian access may not translate directly to typical ED training environments. Non-ED study settings: The evidence came from ICU and operating room patients rather than emergency department resuscitations, which limits bedside generalizability for unstable patients. Sedation and patient factors: Sedation was not standardized and BMI data were incomplete, leaving important real-world modifiers of access difficulty and complication risk unresolved. Practice change question: The practical takeaway is not to abandon IJ, but to consider whether learning the supraclavicular subclavian technique adds a useful second option. We get into where that might fit on the show.

How A General Surgeon Troubleshoots Hernias

Groin hernias in the ED are a bedside diagnosis with a high-stakes split: reducible and incarcerated cases may be managed conservatively, but strangulation is a surgical emergency. Inguinal and femoral hernias behave differently, and reduction technique matters as much as the decision to reduce at all. Emergency Evaluation of Groin Hernias Strangulation red flags: Overlying skin color change, obstructive symptoms, and severe pain should make you presume strangulation rather than a simple incarcerated hernia, and that distinction is worth hearing in the episode. Incarcerated versus strangulated: An incarcerated hernia is chronically nonreducible without bowel ischemia, while strangulation adds compromised blood supply, escalating urgency even before labs are back. Inguinal versus femoral patterns: Femoral hernias are about four times more common in women and carry a slightly higher operative risk, while inguinal hernias are more prevalent in men. CT over ultrasound: CT is the preferred imaging test because it defines direct, indirect, and femoral anatomy while also assessing bowel status and alternative groin diagnoses. Lactate as baseline: Lactate does not diagnose strangulation, but it is useful as a resuscitation baseline when bowel ischemia or ongoing obstruction is on the table. Reduction, Observation, and Surgical Handoff Never reduce strangulation: Do not attempt bedside reduction when strangulation is suspected, because reducing necrotic bowel can seed bacteria into the abdomen; call surgery early. Taxis setup basics: Trendelenburg, ice, analgesia, and patience set up successful reduction of a non-strangulated hernia, with a few practical nuances we get into in the chapter. Neck-first reduction technique: The key maneuver is pressure at the neck of the defect rather than the tip of the bulge, slowly decompressing edematous contents back through the opening. Time-intensive reduction attempts: Hernia reduction is often slow and methodical rather than forceful; some attempts take over an hour, and intolerance may be the sign to stop. Post-reduction PO challenge: After successful ED reduction, a PO challenge is the bedside check that symptoms and transit have truly improved before discharge. High-yield surgical handoff: Surgeons need the symptom timeline, whether the hernia is new or chronic, any abrupt change, and signs of obstruction, ideally paired with imaging already in progress.

Lit Matters #3: Validating PECARN prediction rules

PECARN remains one of the most useful ways to reduce unnecessary pediatric CT after blunt abdominal trauma and minor head injury. This multicenter prospective validation supports both the head trauma rule and, importantly, the abdominal trauma rule, with very high sensitivity for the injuries that actually change management. PECARN in Pediatric Trauma Imaging External abdominal rule validation: The abdominal PECARN rule was prospectively validated across six pediatric trauma centers, a major milestone because this is the first external validation of the blunt torso imaging rule. Head trauma rule confirmation: The minor head trauma PECARN rule again identified children at very low risk for clinically important TBI, reinforcing its role in safely avoiding many head CTs. Clinically meaningful outcomes: The study judged success against outcomes that matter at the bedside: abdominal intervention for torso trauma and clinically important TBI rather than CT abnormalities alone. High sensitivity signal: Both rules showed 100% sensitivity and negative predictive value in this validation cohort, giving clinicians strong support for CT stewardship in the right pediatric trauma patient. Real-world CT reduction opportunity: Even among PECARN-negative children, CTs were still being obtained, underscoring how much over-imaging remains and why decision-rule adoption matters. We get into the practice-change implications in the episode. Community practice caveat: These data come from pediatric trauma centers, where familiarity with PECARN is likely higher, so implementation outside that setting is reasonable but may need local adaptation.